ESMO E-Learning: KRAS Testing in the Selection of Colorectal Patients for Anti-EGFR Targeted Therapy
- Understand importance and aims of KRAS testing in metastatic colorectal cancer patients.
- Understand requirements for technique performance.
- Understand components necessary to introduce technique into practice management.
The discovery of the KRAS mutation as a marker of probable failure of epidermal growth factor receptor targeted therapy is a first step in the tailoring of treatment to the individual; up until recently, we had virtually no understanding of individual responses to therapy.
This module focuses on the importance of KRAS testing in metastatic colorectal cancer patients and is presented by Dr. Sabine Tejpar who is a renowned expert in this field. Included is key studies that led to the conclusion that this is a necessary tool for treatment decision and several specific slides which cover how to perform this high-throughput molecular analysis.
KRAS testing represents a practice-changing tool and with this ESMO E-Learning module, we wish to assist oncologists on how to introduce the technique into their practice. This module is imperative to the educational needs of all specialists interested in the management of patients with metastatic colorectal cancer.
This E-Learning module was published in 2009 and expired in 2011.
The author has reported no conflicts of interest.